Latest Biotech Startup Funding Rounds

Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.

This page showsSector: Biotech
Rounds
156
Jul 27 – Oct 24, 2026
Disclosed funding
$5.9B
121 disclosed amounts
Median round
$24M
Of disclosed amounts
156 rounds
Funding rounds
CompanyAmountRoundSectorCountryInvestorsAnnounced
Superluminal MedicinesBiotech · United StatesCompany profile

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries BBiotechUnited StatesInvestors
TensiveHealthtech · ItalyCompany profile

Clinical-stage bioresorbable implants designed to support natural breast-tissue regeneration and mark the tumour bed after lumpectomy.

Clinical-stage bioresorbable implants designed to support natural breast-tissue regeneration and mark the tumour bed after lumpectomy.

≤€20MConvertible venture debtUndisclosedBiotech, HealthtechItalyInvestors
SiccaNova TherapeuticsBiotech · JapanCompany profile

A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders.

A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders.

¥1.3BSeries ABiotechJapanInvestors
Typewriter TherapeuticsBiotech · United StatesCompany profile

Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders.

Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders.

$56MSeries ABiotechUnited StatesInvestors
DorothAgritech · BrazilCompany profile

Doroth develops lab-on-a-chip molecular tests and monitoring services that help agricultural businesses detect plant pathogens and track biological crop treatments closer to where decisions are made.

Doroth develops lab-on-a-chip molecular tests and monitoring services that help agricultural businesses detect plant pathogens and track biological crop treatments closer to where decisions are made.

$4.5MFunding roundUndisclosedBiotech, AgritechBrazilInvestors
DataHowEnterprise software · SwitzerlandCompany profile

DataHow builds DataHowLab, a process-modeling and digital-twin platform for biopharmaceutical process engineers and manufacturers.

DataHow builds DataHowLab, a process-modeling and digital-twin platform for biopharmaceutical process engineers and manufacturers.

UndisclosedBridge financingUndisclosedBiotech, Enterprise softwareSwitzerlandInvestors
NovaGo TherapeuticsBiotech · SwitzerlandCompany profile

NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury.

NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury.

CHF 24MSeries BBiotechSwitzerlandInvestors
Amyl TherapeuticsBiotech · BelgiumCompany profile

Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease.

Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease.

€8.3MSeries A extensionSeries ABiotechBelgiumInvestors
IntraGel Therapeutics, Ltd.Biotech · IsraelCompany profile

IntraGel Therapeutics develops SRGel, a solvent-free injectable formulation designed to release drugs gradually from a single administration.

IntraGel Therapeutics develops SRGel, a solvent-free injectable formulation designed to release drugs gradually from a single administration.

$7MStrategic investmentUndisclosedBiotechIsraelInvestors
SenticellBiotech · United StatesCompany profile

Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells.

Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells.

$7MSeedBiotechUnited StatesInvestors

Active investors in this selection

All investors →

Ranked by rounds participated in · From Jul 27, 2026

  1. 1
    Eli Lilly and Company

    BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences

    10rounds
    0led
  2. 2
    RA Capital Management

    Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology

    9rounds
    3led
  3. 3
    Y Combinator (YC)

    Molagri, Sensible Biotechnologies, WonderTx

    6rounds
    0led
  4. 4
    Catalio Capital Management

    BigHat Biosciences, Basecamp Research, Enveda

    6rounds
    2led
  5. 5
    Janus Henderson Investors

    Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics

    5rounds
    1led

Latest digests

Archive →

Explore published rounds while the next edition is being prepared.

Browse rounds by topic